ESENTIA Announces Third Quarter 2026 Earnings Conference Call

ESENTIA Announces Third Quarter 2026 Earnings Conference Call

MEXICO CITY, Oct. 22, 2026 /PRNewswire/ -- ESENTIA Energy Development, S.A.B de C.V. (BMV: ESENTIA) ("ESENTIA" or the "Company") will report its third quarter 2026 financial results after market close on Wednesday, October 28th, 2026. ESENTIA will...

WF Holding Limited Announces Termination of Additional Purchase Right

WF Holding Limited Announces Termination of Additional Purchase Right

KUALA LUMPUR, Malaysia, Oct. 21, 2026 /PRNewswire/ -- WF Holding Limited (NASDAQ: WFF) (the "Company"), announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 14,...

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that...

China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right

China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right

TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on...

JinkoSolar Announces Results of 2026 Annual General Meeting

JinkoSolar Announces Results of 2026 Annual General Meeting

SHANGRAO, China, Oct. 21, 2026 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), today announced that all shareholders resolutions proposed at the Company's 2026 annual general meeting held today were duly...

Cohesity Announces FY2026 Partner Award Winners

Cohesity Announces FY2026 Partner Award Winners

Recognition highlights top performers across Cohesity's partner ecosystem, including alliances, distributors, resellers, global system integrators, and managed service providers SINGAPORE, Oct. 21, 2026 /PRNewswire/ -- Cohesity, the leader in AI and...

Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpretation to generate clearer mechanistic hypotheses MORRISVILLE, N.C., Oct. 20, 2026...

TraceLink Announces $1 Million Challenge to Build Agentic Business Processes

TraceLink Announces $1 Million Challenge to Build Agentic Business Processes

Global competition invites developers, solution partners, and business process specialists worldwide to build and demonstrate innovative AI-powered business processes using TraceLink's OPUS platform BOSTON, Oct. 20, 2026 /PRNewswire/ -- TraceLink,...

Sisram Medical Announces NMPA Acceptance of Profhilo Registration Application for Facial Indication

Sisram Medical Announces NMPA Acceptance of Profhilo Registration Application for Facial Indication

Advancing Commercialization Preparations to Expand Injectables Presence in China HONG KONG, Oct. 20, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"),...

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

- Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first - in-class fixed - dose combinations. - ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 111
  • menu
    menu